Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoBio’s Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection Against Influenza

Abstract:
Studies being presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009

NanoBio’s Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection Against Influenza

Ann Arbor, MI | Posted on September 8th, 2009

NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns. The company also announced that data from a large GLP toxicity study in rabbits demonstrated similarly robust immune responses without signs of toxicity or inflammation.

Data from both studies will be presented on Sunday, September 13th at 11:15 am at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at the Moscone Center, San Francisco, CA. The poster references are as follows:

Poster # G1-877: Intranasal W805EC Adjuvanted Fluzone Provides Robust Immunity and Cross-Protection in Ferrets

Poster # G1-878: A GLP Toxicity and Immunogenicity Study of NB-1008, an Intranasal W805EC-Adjuvanted-Fluzone Vaccine

NanoBio will sponsor corporate booth # 1711 at ICAAC, where information on the company's development programs for its vaccine, dermatological and anti-infective programs will be available.

####

About NanoBio Corp.
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

About NanoBio’s Vaccine Platform

NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcus, anthrax, smallpox and other diseases. The company’s NanoStat™ adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen sparing qualities; cross-protection against strains not included in the vaccine; ability to adjuvant multiple antigen types without inducing inflammation; thermal stability of the vaccine; and removing the need for needles.

NanoBio Corp. announced earlier in 2009 that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered intranasally. This Phase 1 study is ongoing.

For more information, please click here

Contacts:
Telephone: 734.302.4000
Fax: 734.302.9150

Copyright © NanoBio Corp.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iranian Researchers Synthesize Stable Ceramic Nanopowders at Room Temperature September 20th, 2014

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014

Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014

Nanomedicine

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

The Pocket Project will develop a low-cost and accurate point-of-care test to diagnose Tuberculosis: ICN2 holds a follow-up meeting of the Project on September 18th - 19th September 18th, 2014

New non-invasive technique could revolutionize the imaging of metastatic cancer September 17th, 2014

Recruiting bacteria to be technology innovation partners: September 17th, 2014

Announcements

Iranian Scientists Separate Zinc Ion at Low Concentrations September 20th, 2014

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014

Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014

Nanobiotechnology

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

CiQUS researchers design an artificial nose to detect DNA differentiation with single nucleotide resolution September 18th, 2014

Biosensors Get a Boost from Graphene Partnership: $5 Million Investment Supports Dozens of Jobs and Development of 300mm Fabrication Process and Wafer Transfer Facility September 18th, 2014

Recruiting bacteria to be technology innovation partners: September 17th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE